Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   94663 News 


«12345678910111213...10631064»
  • ||||||||||  anitocabtagene autoleucel (CART-ddBCMA) / Arcellx, Gilead
    iMMagine-3: A Phase 3, Randomized Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel (Anito-Cel) With Standard of Care in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) (Exhibit Hall, Pavilion 3) -  Sep 26, 2024 - Abstract #IMW2024IMW_350;    
    P2, P3
    Introduction: In the phase 3 CARTITUDE-4 trial, ciltacabtagene autoleucel (cilta-cel) prolonged progression-free survival (PFS) vs standard of care (SOC) (HR [weighted], 0.26; P< 0.0001; HR [unweighted], 0.40; P< 0.0001) in patients with lenalidomide (len)-refractory multiple myeloma (MM) and 1 Before randomization, investigators will select one of the following SOC regimens: pomalidomide (P), bortezomib (V), and dexamethasone (d; PVd); daratumumab (D), P, and d (DPd); carfilzomib (K), D, and d (KDd); or K and d (Kd)...Pts in the anito-cel arm will undergo leukapheresis and optional bridging therapy (with the selected SOC regimen at discretion of the investigator) followed by lymphodepleting chemotherapy (fludarabine 30 mg/m2/d and cyclophosphamide 300 mg/m2/d for 3 d) and one infusion of anito-cel (115
  • ||||||||||  Tecvayli (teclistamab-cqyv) / Genmab, J&J
    Teclistamab in real life: Can we shorten the ramp-up ? (Exhibit Hall, Pavilion 3) -  Sep 26, 2024 - Abstract #IMW2024IMW_348;    
    The rates of CRS in Gp2 was low compared to the Gp1 and occured at D3 or less frequently at D5 i.e. one day less CRS. Moreover, shortened Ramp-up do not compromise pts outcome and toxicity.
  • ||||||||||  Darzalex (daratumumab) / J&J, Carvykti (ciltacabtagene autoleucel) / J&J
    Comparative Efficacy of CARVYKTI in CARTITUDE-4 versus Alternative Treatments from Daratumumab Clinical Trials for the Treatment of Patients with Lenalidomide-Refractory Multiple Myeloma (Exhibit Hall, Pavilion 3) -  Sep 26, 2024 - Abstract #IMW2024IMW_317;    
    Data were available for patients from CARTITUDE-4 who received cilta-cel, and from nine daratumumab trials (CASTOR, CANDOR, APOLLO, ALCYONE, MAIA, GRIFFIN, CASSIOPEIA, POLLUX and EQUULEUS) who received active or subsequent treatments with or without daratumumab (mixed cohort of regimens where the most frequently used were carfilzomib and dexamethasone [Kd], daratumumab with Kd [DKd], pomalidomide and dexamethasone [Pd], and DPd, among others)... Cilta-cel showed superior efficacy compared to alternative treatments from the daratumumab clinical trials across all outcomes, highlighting the potential for cilta-cel to be considered a new standard of care option for lenalidomide-refractory RRMM patients, who have received 1-3 prior LOTs, including an IMiD and a PI.
  • ||||||||||  dexamethasone / Generic mfg., lenalidomide / Generic mfg., carfilzomib / Generic mfg.
    Journal:  A.R.R.O.W.2: Once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma. (Pubmed Central) -  Sep 25, 2024   
    P3
    In conclusion, although statistical significance for noninferiority of ORR was not achieved, the efficacy and safety of once-weekly KRd56 were similar to those of twice-weekly KRd27 and once-weekly KRd56 may be an effective and convenient treatment option for patients with RRMM. This trial was registered at www.clinicaltrials.gov as #NCT03859427.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Impact of cortisol on liver fat and metabolic health in adrenal incidentalomas and Cushing's syndrome. (Pubmed Central) -  Sep 25, 2024   
    The results indicate that the S. nigra fruit extract, by stimulating collagen synthesis and reducing inflammation, effectively accelerates the healing process of injured tendons. MACS and CS are linked to significant metabolic disturbances, including increased liver fat and impaired glucose and lipid metabolism, contributing to fatty liver.
  • ||||||||||  Journal:  Adult-Onset T-Cell Acute Lymphoblastic Lymphoma-Leukemia Presenting With Petechial Rash: A Case Report. (Pubmed Central) -  Sep 25, 2024   
    The patient received hyper-CVAD cycle 1A with several complications but ultimately achieved remission after four cycles. Here, we stress the importance of broadening differentials for new-onset petechial rashes in adults to include systematic lymphomas, such as T-ALL, and the need for early recognition so patients can receive timely treatment.
  • ||||||||||  methylprednisolone sodium succinate / Generic mfg.
    Journal:  Anti-GBM Nephritis in an 11-Year-Old Female Child: A Rare Case Report. (Pubmed Central) -  Sep 25, 2024   
    The patient was treated with intravenous methylprednisolone and antihypertensives and then scheduled for regular dialysis. This case underscores the critical need for early diagnosis and aggressive management to prevent severe complications in pediatric anti-GBM disease.
  • ||||||||||  dapsone / Generic mfg.
    Journal:  A Case of Anatopic Phenomenon in Dapsone Hypersensitivity Syndrome. (Pubmed Central) -  Sep 25, 2024   
    This case report describes anatopic response, a phenomenon where a cutaneous infection modifies the inflammatory response of a secondary inflammatory dermatoses at the same location. We further elucidate the pathogenic mechanisms implicated in anatopic response, a phenomenon not commonly documented in the literature.
  • ||||||||||  Dupixent (dupilumab) / Sanofi, Regeneron
    Journal:  Case report: Bullous pemphigoid combined with Sj (Pubmed Central) -  Sep 25, 2024   
    The role of SS in the pathogenesis of skin lesions is unclear, and the relationship between these blistering diseases and SS remains elusive. Further research is needed to determine whether there are common pathological mechanisms between the two conditions.
  • ||||||||||  triamcinolone acetonide / Generic mfg.
    The Outcomes of Carpal Tunnel Injections and Carpal Tunnel Surgery (In Person) -  Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2903;    
    CT injections using the transverse ulnar approach are safe and effective with a low risk of complications. CT surgical release in recurrent cases provides lasting relief to many patients, but also fails in a substantial minority (28.2%) who then require reinjection or other non-surgical therapy.
  • ||||||||||  triamcinolone acetonide / Generic mfg.
    Intra-articular Corticosteroid Injections for Knee Osteoarthritis: Does the Dose Matter? (In Person) -  Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2788;    
    To determine if the dose of Triamcinolone acetonide (TA) used in IA injections for the treatment of knee OA made any significant difference in the patient outcomes, we studied the effects of 10 mg vs 20 mg vs 40 mg of TA intra-articular injections in knee OA... IA corticosteroid dose of 40 mg of TA was found to be superior in improving knee OA symptoms when compared to the 10 mg and the 20 mg TA dose with an average improvement in WOMAC by 29.29 percentage points in the 20 mg TA dose group compared to 6.07 percentage point improvement in the 10 mg TA dose group and 9.56 percentage point improvement in the 20 mg TA dose group.
  • ||||||||||  Humira (adalimumab) / AbbVie, Rituxan (rituximab) / Roche
    Insights into Rheumatology Practice in Uganda (In Person) -  Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2781;    
    The spectrum of available laboratory testing is extensive. Oral DMARDs are the mainstay of therapy, whereas biologics are not regularly used.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca, Rituxan (rituximab) / Roche
    Acute Transverse Myelitis in Pediatric Systemic Lupus Erythematosus (In Person) -  Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2591;    
    Even with maximal therapy, neurologic outcomes were sub-optimal. Future directions may include better correlation of clinical phenotype with imaging findings (white vs.
  • ||||||||||  MG 519 / BMS, Rituxan (rituximab) / Roche
    Outcomes of Intermittent Intravenous Steroid Use During Infusion Therapy in Systemic Sclerosis (In Person) -  Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2133;    
    With increasing use of biologic medications such as rituximab (RTX), we studied whether intermittent high dose IV corticosteroid premedication is associated with development of SRC in SSc patients. We performed a retrospective observational study of EMR data from 155 SSc patients seen long-term in Rheumatology Clinic at University of New Mexico Hospital between January 2009 and December 2023...In the infusion group, one patient developed SRC prior to first infusion, but across a total of 827 infusions with a mean of 21
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Sustained Drug-free Remission in Giant Cell Arteritis: Results Results of the Spanish ARTESER Registry (In Person) -  Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2051;    
    We performed a retrospective observational study of EMR data from 155 SSc patients seen long-term in Rheumatology Clinic at University of New Mexico Hospital between January 2009 and December 2023...In the infusion group, one patient developed SRC prior to first infusion, but across a total of 827 infusions with a mean of 21 Forty-two percent had received concomitant treatment with tocilizumab and/or immunosuppressants, mainly methotrexate...The cumulative doses of prednisone at one year were significantly lower in patients who attained SDFR (637.4
  • ||||||||||  umbilical cord lining stem cell therapy / Restem
    Safety and Efficacy Data from a Phase I Trial of Umbilical Lining-Derived Stem Cells (ULSC) in Adult Dermatomyositis/Polymyositis (Room 145 AB; In Person) -  Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1397;    
    P1
    Umbilical cord-derived mesenchymal stromal cells, a classification of cells that includes umbilical cord lining stem cells (ULSC) may be associated with a younger cellular phenotype with minimal expression of HLA-DR after activation, which is expected to correlate with reduced immunogenic potential...The infusion was temporarily paused, 150 mg intravenous hydrocortisone administered, and the infusion re-initiated with no recurrence... Taken together, the overall human experience with the intravenous infusion of ULSC has demonstrated an absence of adverse outcomes attributable to this investigational product, and in the context of DM/PM, has demonstrated early evidence of clinical improvement in multiple participants using complementary outcome measures, in the context of progressive reduction in steroid dosing.
  • ||||||||||  methylprednisolone sodium succinate / Generic mfg.
    Predictors of Fracture in SLE: A Longitudinal Cohort Study (Room 147AB; In Person) -  Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1130;    
    Traditional risk factors (such as Caucasian race, female sex and low BMD) do increase fracture risk in SLE. Stroke
  • ||||||||||  dexamethasone / Generic mfg.
    Activation of the Hes1/Piezo1 Pathway Promotes Mechanical Stress Response and Prevents Glucocorticoid-induced Osteoporosis (Hall E; In Person) -  Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1093;    
    DEX impeded Piezo1 expression by repressing the expression and phosphorylation of the transcription factor Hes1, thereby elevating sclerostin levels and the RANKL/OPG ratio. Conversely, Yoda1 augmented Hes1's expression and phosphorylation, enhancing Piezo1's transcriptional activity and expression, ultimately forestalling the bone mass and strength decline associated with GIOP (Fig.
  • ||||||||||  bortezomib / Generic mfg., dexamethasone / Generic mfg., melphalan / Generic mfg.
    Autologous Stem Cell Transplantation for Multiple Myeloma in Current Era Benefits Are More in Developing Countries with Limited Resources (Exhibition Hall (3F)) -  Sep 24, 2024 - Abstract #ICBMT2024ICBMT_260;    
    Bortezomib, dexamethasone, and IMiD was the most common induction regimen in 36 patients (80%)...Melphalan was dosed at 200mg/m2 in 36 of 45patients (80%) while 9 patients (20%) received a reduced dose (140mg/m2)...USD 10k). Conclusions : ASCT results in prolongation of remission duration and deepening of the responses which is especially relevant in developing countries where access to newer therapies is limited.